Sort
82,697 grants matching “vaccine development”
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
$1,305,947Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Nonhuman Primate
$1,305,819Michael K Axthelm · Oregon Health & Science University · P01 · FY2016 · AI
Development of stable and rapidly acting adjuvanted vaccines for biodefense
$1,305,761Robert Newton Brey · Soligenix, Inc. · U01 · FY2009 · AI
Epigenetic Therapy for Thoracic Malignancies
$1,305,530David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2025 · CA
VTEU: ZIKA VIRUS NATURAL HISTORY STUDY
$1,304,960Daniel Hoft · Saint Louis University · N01 · FY2016 · AI
Center of Research Translation on the Osteoimmunology of Bone Infection (CoRTOBI)
$1,304,334Edward M Schwarz · University Of Rochester · P50 · FY2023 · AR
Glycolipid Presentation by CD1d
$1,304,014Albert S. Bendelac · University Of Chicago · P01 · FY2008 · AI
Optimization of HIV glycoproteins as vaccine candidates
$1,303,900Jose A Lasalde-Dominicci · University Of Puerto Rico · R01 · FY2018 · AI
HUMAN MELANOMA--ETIOLOGY, PROGRESSION AND THERAPY
$1,303,630Wistar Institute · P01 · FY2001 · CA
DNA Vaccine delivery for biodefense with dengue
$1,303,521Cyto Pulse Sciences, Inc. · R44 · FY2004 · AI
Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs
$1,303,436Leonidas A Stamatatos · Fred Hutchinson Cancer Center · P01 · FY2022 · AI
Immune Reconstitution
$1,303,403Ronald Gress · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Exploring mechanisms that govern immune homeostasis in skin
$1,303,301Keisuke Nagao · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Immunity to novel T/F SHIVs: variability in the co-evolution of virus and host immunity
$1,303,208Garnett H Kelsoe · Duke University · R01 · FY2019 · AI
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit.
$1,303,154Beatriz Grinsztejn · Fundacao Oswaldo Cruz · UM1 · FY2024 · AI
Development of a flagellin-cocaine conjugate vaccine
$1,303,127Steven B. Mizel · Wake Forest University Health Sciences · RC2 · FY2009 · DA
Improving the efficacy of anti-nicotine immunotherapy
$1,303,043Alexey G Mukhin · Duke University · RC2 · FY2009 · DA
DISCOVAR:Disparities in Immune Response to SARS-CoV-2 in ARkansas
$1,302,152Wendy N Nembhard · Univ Of Arkansas For Med Scis · U01 · FY2020 · CA
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,301,779Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Ketone Body Metabolism in CD8+ T Cell Responses
$1,301,502Russell Jones · Van Andel Research Institute · R01 · FY2025 · AI
Immune Correlates of Protection from TB
$1,301,322Deepak Kaushal · Tulane University Of Louisiana · R01 · FY2018 · AI
Immune correlates of protection
$1,301,316Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Immune Reconstitution
$1,301,254Ronald Gress · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Structural Approaches to HIV-1 Immunogen Design and BNAb Analysis
$1,301,070Ellis L Reinherz · Dana-Farber Cancer Inst · P01 · FY2017 · AI
Therapeutic Monoclonal Antibodies to H5N1 Influenza
$1,301,015Richard John Webby · St. Jude Children'S Research Hospital · U01 · FY2008 · AI